A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

Immune Tolerance Network (ITN)

Juvenile Diabetes Research Foundation

Information provided by (Responsible Party):

National Institute of Allergy and Infectious Diseases (NIAID)

ClinicalTrials.gov Identifier:

NCT01183468

First received: August 16, 2010

Last updated: November 8, 2012

Last verified: November 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	November 2014
Estimated Primary Completion Date:	November 2013 (Final data collection date for primary outcome measure)

No publications provided by National Institute of Allergy and Infectious Diseases (NIAID)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ozeri E, Mizrahi M, Shahaf G, Lewis EC. α-1 Antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol. 2012 Jul 1;189(1):146-53. Epub 2012 May 25.

To Top